1805. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial.
作者: Maura Marcucci.;Thomas W Painter.;David Conen.;Vladimir Lomivorotov.;Daniel I Sessler.;Matthew T V Chan.;Flavia K Borges.;Kate Leslie.;Emmanuelle Duceppe.;María José Martínez-Zapata.;Chew Yin Wang.;Denis Xavier.;Sandra N Ofori.;Michael Ke Wang.;Sergey Efremov.;Giovanni Landoni.;Ydo V Kleinlugtenbelt.;Wojciech Szczeklik.;Denis Schmartz.;Amit X Garg.;Timothy G Short.;Maria Wittmann.;Christian S Meyhoff.;Mohammed Amir.;David Torres.;Ameen Patel.;Kurt Ruetzler.;Joel L Parlow.;Vikas Tandon.;Edith Fleischmann.;Carisi A Polanczyk.;Andre Lamy.;Raja Jayaram.;Sergey V Astrakov.;William Ka Kei Wu.;Chao Chia Cheong.;Sabry Ayad.;Mikhail Kirov.;Miriam de Nadal.;Valery V Likhvantsev.;Pilar Paniagua.;Hector J Aguado.;Kamal Maheshwari.;Richard P Whitlock.;Michael H McGillion.;Jessica Vincent.;Ingrid Copland.;Kumar Balasubramanian.;Bruce M Biccard.;Sadeesh Srinathan.;Samandar Ismoilov.;Shirley Pettit.;David Stillo.;Andrea Kurz.;Emilie P Belley-Côté.;Jessica Spence.;William F McIntyre.;Shrikant I Bangdiwala.;Gordon Guyatt.;Salim Yusuf.;P J Devereaux.; .
来源: Ann Intern Med. 2023年176卷5期605-614页
Among patients having noncardiac surgery, perioperative hemodynamic abnormalities are associated with vascular complications. Uncertainty remains about what intraoperative blood pressure to target and how to manage long-term antihypertensive medications perioperatively.
1810. Web Exclusive. Annals for Hospitalists Inpatient Notes - Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction-What Hospitalists Need to Know.1811. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
作者: Neda Laiteerapong.;Jason Alexander.;Louis Philipson.;Aaron N Winn.;Elbert S Huang.
来源: Ann Intern Med. 2023年176卷4期eL230007页 1817. Universal Masking in Health Care Settings: A Pandemic Strategy Whose Time Has Come and Gone, For Now.
作者: Erica S Shenoy.;Hilary M Babcock.;Karen B Brust.;Michael S Calderwood.;Shira Doron.;Anurag N Malani.;Sharon B Wright.;Westyn Branch-Elliman.
来源: Ann Intern Med. 2023年176卷6期859-861页
During the COVID-19 pandemic in the United States, the use of facemasks has been mandated in all health care settings for individuals older than 2 years, whether present as health care personnel, patients, or visitors. In this commentary, a group of health care epidemiologists, infectious diseases physicians, and researchers argue for the withdrawal of the universal masking policy given the current status of the COVID-19 pandemic.
1819. The New European Medical Device Regulation: Balancing Innovation and Patient Safety.
作者: Michael Bretthauer.;Sara Gerke.;Cesare Hassan.;Omer F Ahmad.;Yuichi Mori.
来源: Ann Intern Med. 2023年176卷6期844-848页
The European Union has introduced stricter provisions for medical devices under the new Medical Device Regulation (MDR). The MDR increases requirements for clinical trial testing for many devices before they can legally be placed on the market and extends requirements for rigorous clinical surveillance of benefits and harms to the entire life cycle of devices. New "expert panels" have been established by the European Commission to advise in the assessment of devices toward certification, and the role of previous "notified bodies" (private companies charged by the Commission with ensuring that manufacturers follow the requirements for device testing) is being expanded. The MDR does not contain a grandfathering clause; thus, all existing medical devices must be recertified under the stricter regulation. The recertification deadline has recently been extended to 2027 or 2028, depending on the device's risk class. Whether most device manufacturers can meet these new requirements is uncertain, and the MDR will likely have important consequences for manufacturers, researchers, clinicians, and patients. Enhanced collaborations between the medical device industry and physician partners will be needed to meet the new requirements in a timely manner to avoid shortages of existing devices and to mitigate barriers to development of new devices.
|